RPTOR

Across TCGA pan-cancer cohorts, RPTOR mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPTOR data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RPTOR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPTOR expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

UCEC, LSCC, and PDAC are the cancer types where RPTOR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	II,III,IV	0.385	0.856	.011	28	view →
LSCC	DFS	Tertile	All	0.276	0.933	.001	15	view →
PDAC	OS	Tertile	IV	0.916	0.231	.024	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.798	.015	5	view →
CCRCC	DFS	Median	All	0.976	0.896	.042	2	view →
GBM	DFS	Tertile	All	0.197	0.417	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPTOR–UCEC (DFS)

Open the UCEC breakdown →